Cervical screening in England: performance up, volume down
This article was originally published in Clinica
The UK's Department of Health is facing a quandary: why is it that improvements in performance, supported by the ongoing adoption of more attractive, efficient and effective technologies, are not being matched by a rise in the number of women screened. Coverage rates are still within NHS targets, but only just - and are falling.
You may also be interested in...
Former managing director of Janssen India to helm Bharat Serums and Vaccines following the firm’s acquisition by private equity firm Advent International.
At the end of the Brexit transition period, the UK will be charting its own course through the often choppy seas of medicines regulation. While it plans to retain the existing EU rules that have been transposed into domestic legislation, it also wants the freedom to tailor its regulations in areas like clinical trials, advanced therapies and product labeling.